Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
In an unexpected political alliance, leaders from both parties are rallying behind mifepristone’s Food and Drug Administration approval as an ongoing legal battle threatens access to the abortion pill.
President Donald Trump’s legal team surprised many by continuing former President Joe Biden administration’s defense of mifepristone’s FDA approval, urging courts to dismiss a lawsuit from conservative states that seek to sharply restrict its availability.
While Republicans have traditionally taken a strong anti-abortion stance, the wide acceptance of medication abortion has created political and practical complications. Trump’s lawyers argued the FDA had appropriately followed the law when approving mifepristone over two decades ago, emphasizing regulatory stability and warning of the broader implications of undermining federal drug approvals.
This development comes after the Supreme Court preserved nationwide access to mifepristone, temporarily rejecting lower court decisions that could have severely curtailed the pill’s use. The justices emphasized several conservative states lacked sufficient standing to overturn the FDA’s authority, reinforcing the agency’s role in drug regulation.
By defending mifepristone’s FDA approval, the government prevents a potential domino effect that could have restricted access not only to abortion pills but also to other essential medications. Reports show allowing courts to overturn drug approvals would create chaos for reproductive and non-reproductive health care alike.
Beyond the courtroom, the debate over medication abortion taps into broader societal struggles over women’s autonomy and bodily rights. Mifepristone, when used in combination with misoprostol, is highly effective and safe for ending early pregnancies. Medical bodies like the American College of Obstetricians and Gynecologists emphasize access to it as a critical component of reproductive healthcare.
Research further shows restricting access to reproductive health services – including mifepristone – has profound economic and societal consequences. Limits on reproductive autonomy can depress women’s labor market participation, increase poverty rates, and exacerbate gender inequality on a national scale, according to a study published by Project Syndicate.
Conservative plaintiffs have argued the FDA overlooked safety concerns when approving the abortion pill and easing access rules over the years. However, multiple peer-reviewed studies, including those from the NIH’s National Library of Medicine, have repeatedly shown mifepristone is safer than many common medications such as penicillin or Viagra.
Medical groups – such as ACOG – argue that beyond abortion, mifepristone plays a crucial role in treating miscarriages and other reproductive health conditions. Therefore, restricting its availability could harm a broad range of patients seeking care for reasons unrelated to elective abortion.
The fate of mifepristone, and millions of Americans’ reproductive choices, will depend on whether the current legal protections withstand ongoing challenges from the states and activist groups, according to BBC News.
